Atlas Trials

CTA Expression/Methylation and Response to Pembrolizumab of NSCLC Patients

Clinical trial NCT03571360 · UNKNOWN

Trial details

NCT number
NCT03571360
Sponsor
Medical University of Vienna
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Non Small Cell Lung Cancer
Start date
2020-02-10
Primary completion
2021-01-14
Enrollment
42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.